Glaukos Corporation Announces Third Quarter 2018 Financial Results
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the third quarter ended September 30, 2018. Key highlights include: Achieved 9% net sales growth to $43.9 million in the third quarter of 2018, compared to $40.4 mil